Jacobson Resonance Enterprises, Inc. Updates Research Findings with Mammary Carcinoma Cell Types from the College of Veterinary Medicine at Mississippi State University


BOYNTON BEACH, Fla., July 27, 2004 (PRIMEZONE) -- Dr. Jerry I. Jacobson, Chairman, Chief Executive Officer and Chief Science and Technology Officer of Jacobson Resonance Enterprises, Inc., (OTCBB:JRSE) reported today new insights from the ongoing study on human breast cancer cells utilizing the Jacobson Resonator.

Two pico-Tesla range electromagnetic energy fields (PTREMEF) schedules have consistently suppressed the proliferation rate of neoplastic cells in-vitro. Using mRNA microarray technologies, investigations discovered approximately eleven gene sequences that have expression profiles altered in human mammary carcinoma cell populations following exposure to specific PTREMEF schedules designed by Jacobson Resonance. The implication that physiologic magnetic fields may influence transcription events within cancer cell types is profound.

Additionally, proteomics studies employing 2D-PAGE analysis and LC/mass spectrometry methods have detected a range of biological proteins produced by breast cancer cell types that have their expression profiles altered following exposure to the same schedules applied in gene-expression studies. The implication that transcription/ translation events may be altered by magnetic fields that decrease the viability of these cell types further adds excitement.

Quoting Dr. Jacobson, "Basically, using a multi-setting schedule established from a particular physico-mathematical apparatus, collaborating laboratories at Mississippi State University under the direction of Dr. C.P. Coyne, have identified alterations in the expression profile for genetic mRNA sequences and biological proteins in human mammary carcinoma cell populations. Further proteomics analysis has identified not only changes in the quantity of certain cancer cell proteins expressed following PTREMEF exposure, but also changes in the function of certain cancer cell protein fractions. In this context, what has been established during the course of recently conducted research investigations has been the following:


 1. There is a definitive influence of pico-Tesla magnetic fields on 
    biological systems.
 2. We are viewing critically important molecular mechanisms as to 
    how pico-Tesla magnetic fields can exert anticancer properties.
 3. We have identified genes and proteins that are probably involved 
    in suppressing growth and viability of human mammary carcinoma 
    that can be regulated by pico-Tesla magnetic fields.
 4. The genes and proteins identified are "targets" that can function 
    as templates for the molecular design of new chemotherapeutic 
    agents.
 5. pico-Tesla magnetic fields can potentially be applied either 
    alone or in combination with conventional chemotherapeutic 
    agents to lower the total dosage requirements.           
 6. pico-Tesla magnetic fields instrumentation can be applied as a 
    research tool for Scientific discovery.

We are excited about our research findings."

JRSE is an emerging worldwide leader in magnetic resonance technology, whose main focus is the eradication of human suffering. The company's technology base has the potential for multiple industry applications including the fields of healthcare, veterinary medicine, the leisure, beauty and athletic fitness arenas, food and beverage, pharmaceuticals, energy and the environment.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the company to differ materially from those contemplated or implied by such forward-looking statements. Included in these risks and other factors are funding availability, competition from better-financed companies and required regulatory clearances. For further information, contact Anthony P. Fusco, Jr. at (561) 752.4141.


            

Contact Data